Next Gen Sequencing


Detecting cancer four years before conventional diagnosis

Announcing a big move for Dale affecting his family, his employer, his colleagues, and his friends Note: This article originally appeared on LinkedIn. The magic wand of early detection Several years ago at a meeting with sales management, someone asked a provocative question: “If you had a magic wand, what […]


Ion GeneStudio S5: The latest iteration of Thermo Fisher Scientific NGS 1

With the beginning of the influential JP Morgan Healthcare investor conference this week in San Francisco, you can expect an avalanche of news from companies large and small regarding all things therapuetic and diagnostic. With an official count of about 9,000 attendees, there are many more in San Francisco who […]


Thoughts from the Association of Molecular Pathology conference #AMP2017

John Iafrede (Massachusetts General Hospital, MA) “There is a tidal wave of cell-free approaches; little performance testing; and the big question is who is going to pay for it.” This year’s Assocation for Molecular Pathology was held in Salt Lake City, Utah from November 15-18, 2017. (You can find the […]

#AMP2017

Association for Molecular Pathology annual meeting 2017 #AMP2017

Preview of Association for Molecular Pathology 2017 #AMP2017

With over 2000 clinical laboratory professionals in molecular diagnostics and pathology, plenty of technology and offerings on display. This year the Association for Molecular Pathology takes place in Salt Lake City Utah, and promises an abundance of new technology as well as the new accompanying science around diagnostic testing. Since […]


Cancer immunotherapy and a clinical trial dilemma

There is a numbers problem, and a biomarker one as well. Annually the worldwide cancer drug market is on the order of $110 Billion, and individual immuno-oncology drugs cost the US healthcare system on the order of $100K to $150K per year. With such large financial incentives, there are currently over 900 […]